Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Chemopreventive and potential therapeutic effects of soy isoflavones have been shown to be effective in numerous preclinical studies as well as clinical studies in prostate cancer. Although the inhibition of androgen receptor signaling has been supposed as one mechanism underlying their effects, the precise mechanism of androgen receptor inhibition remains unclear. Thus, this study aimed to clarify their mechanism. Among soy isoflavones, equol suppressed androgen receptor as well as prostate-specific antigen expression most potently in androgen-dependent LNCaP cells. However, the inhibitory effect on androgen receptor expression and activity was less prominent in castration-resistant CxR and 22Rv1 cells. Consistently, cell proliferation was suppressed and cellular apoptosis was induced by equol in LNCaP cells, but less so in CxR and 22Rv1 cells. We revealed that the proteasome pathway through S-phase kinase-associated protein 2 (Skp2) was responsible for androgen receptor suppression. Taken together, soy isoflavones, especially equol, appear to be promising as chemopreventive and therapeutic agents for prostate cancer based on the fact that equol augments Skp2-mediated androgen receptor degradation. Moreover, because Skp2 expression was indicated to be crucial for the effect of soy isoflavones, soy isoflavones may be applicable for precancerous and cancerous prostates.

Original languageEnglish
Pages (from-to)1022-1028
Number of pages7
JournalCancer Science
Volume107
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

S-Phase Kinase-Associated Proteins
Equol
Androgen Receptors
Isoflavones
Prostatic Neoplasms
Growth
Castration
Therapeutic Uses
Proteasome Endopeptidase Complex
Prostate-Specific Antigen
Androgens
Prostate
Cell Proliferation
Apoptosis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{397516d6d74941228b78fbd86978b3f8,
title = "Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2",
abstract = "Chemopreventive and potential therapeutic effects of soy isoflavones have been shown to be effective in numerous preclinical studies as well as clinical studies in prostate cancer. Although the inhibition of androgen receptor signaling has been supposed as one mechanism underlying their effects, the precise mechanism of androgen receptor inhibition remains unclear. Thus, this study aimed to clarify their mechanism. Among soy isoflavones, equol suppressed androgen receptor as well as prostate-specific antigen expression most potently in androgen-dependent LNCaP cells. However, the inhibitory effect on androgen receptor expression and activity was less prominent in castration-resistant CxR and 22Rv1 cells. Consistently, cell proliferation was suppressed and cellular apoptosis was induced by equol in LNCaP cells, but less so in CxR and 22Rv1 cells. We revealed that the proteasome pathway through S-phase kinase-associated protein 2 (Skp2) was responsible for androgen receptor suppression. Taken together, soy isoflavones, especially equol, appear to be promising as chemopreventive and therapeutic agents for prostate cancer based on the fact that equol augments Skp2-mediated androgen receptor degradation. Moreover, because Skp2 expression was indicated to be crucial for the effect of soy isoflavones, soy isoflavones may be applicable for precancerous and cancerous prostates.",
author = "Momoe Itsumi and Masaki Shiota and Ario Takeuchi and Eiji Kashiwagi and Junichi Inokuchi and Katsunori Tatsugami and Shunichi Kajioka and Takeshi Uchiumi and Seiji Naito and Masatoshi Eto and Akira Yokomizo",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/cas.12948",
language = "English",
volume = "107",
pages = "1022--1028",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2

AU - Itsumi, Momoe

AU - Shiota, Masaki

AU - Takeuchi, Ario

AU - Kashiwagi, Eiji

AU - Inokuchi, Junichi

AU - Tatsugami, Katsunori

AU - Kajioka, Shunichi

AU - Uchiumi, Takeshi

AU - Naito, Seiji

AU - Eto, Masatoshi

AU - Yokomizo, Akira

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Chemopreventive and potential therapeutic effects of soy isoflavones have been shown to be effective in numerous preclinical studies as well as clinical studies in prostate cancer. Although the inhibition of androgen receptor signaling has been supposed as one mechanism underlying their effects, the precise mechanism of androgen receptor inhibition remains unclear. Thus, this study aimed to clarify their mechanism. Among soy isoflavones, equol suppressed androgen receptor as well as prostate-specific antigen expression most potently in androgen-dependent LNCaP cells. However, the inhibitory effect on androgen receptor expression and activity was less prominent in castration-resistant CxR and 22Rv1 cells. Consistently, cell proliferation was suppressed and cellular apoptosis was induced by equol in LNCaP cells, but less so in CxR and 22Rv1 cells. We revealed that the proteasome pathway through S-phase kinase-associated protein 2 (Skp2) was responsible for androgen receptor suppression. Taken together, soy isoflavones, especially equol, appear to be promising as chemopreventive and therapeutic agents for prostate cancer based on the fact that equol augments Skp2-mediated androgen receptor degradation. Moreover, because Skp2 expression was indicated to be crucial for the effect of soy isoflavones, soy isoflavones may be applicable for precancerous and cancerous prostates.

AB - Chemopreventive and potential therapeutic effects of soy isoflavones have been shown to be effective in numerous preclinical studies as well as clinical studies in prostate cancer. Although the inhibition of androgen receptor signaling has been supposed as one mechanism underlying their effects, the precise mechanism of androgen receptor inhibition remains unclear. Thus, this study aimed to clarify their mechanism. Among soy isoflavones, equol suppressed androgen receptor as well as prostate-specific antigen expression most potently in androgen-dependent LNCaP cells. However, the inhibitory effect on androgen receptor expression and activity was less prominent in castration-resistant CxR and 22Rv1 cells. Consistently, cell proliferation was suppressed and cellular apoptosis was induced by equol in LNCaP cells, but less so in CxR and 22Rv1 cells. We revealed that the proteasome pathway through S-phase kinase-associated protein 2 (Skp2) was responsible for androgen receptor suppression. Taken together, soy isoflavones, especially equol, appear to be promising as chemopreventive and therapeutic agents for prostate cancer based on the fact that equol augments Skp2-mediated androgen receptor degradation. Moreover, because Skp2 expression was indicated to be crucial for the effect of soy isoflavones, soy isoflavones may be applicable for precancerous and cancerous prostates.

UR - http://www.scopus.com/inward/record.url?scp=84978829841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978829841&partnerID=8YFLogxK

U2 - 10.1111/cas.12948

DO - 10.1111/cas.12948

M3 - Article

C2 - 27088761

AN - SCOPUS:84978829841

VL - 107

SP - 1022

EP - 1028

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -